Novo Nordisk A/S (NVO) Fundamental Analysis
Novo Nordisk A/S is assessed below across growth, profitability, cash generation and balance-sheet strength, sourced directly from its SEC filings. It is solidly profitable, with a latest net margin of 33%. Cash generation is healthy, funding the business from its own operations. The latest filing shows a mixed picture across the four dimensions.
Beat Index assesses Novo Nordisk A/S across sixteen analysis tabs, spanning revenue and income, margins, cash flow, returns, liquidity and leverage, working capital, intrinsic value, commitments, insider activity, risk, and its latest 20-F reads strongest on profit margins and cash generation while flagging revenue growth and balance-sheet strength for closer review. Every figure is taken as-reported from SEC EDGAR filings, with no vendor adjustments.
At a glance
- PositiveProfitability: Net margin 33%
- WatchGrowth: Revenue +6% YoY
- ConcernNo red flags in the latest quarter.
Trend matrix, last 4 quarters
| Dimension | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Growth | Revenue +6% YoY | Revenue up 25% YoY | Revenue up 31% YoY | Revenue up 26% YoY |
| Profitability | Net margin 33% | Net margin 35% | Net margin 36% | Net margin 31% |
| Cash Generation | FCF margin 19% | FCF margin 25% | FCF margin 36% | FCF margin 38% |
| Balance Sheet | Current ratio 0.8x (low debt, cash-generative) | Current ratio 0.7x (low debt, cash-generative) | Current ratio 0.8x (low debt, cash-generative) | Current ratio 0.9x (low debt, cash-generative) |
Quarterly financials
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | kr309.06B | kr290.40B | kr232.26B | kr176.95B | kr140.80B |
| Cash & equivalents | kr26.46B | kr15.65B | kr14.39B | kr12.65B | kr10.72B |
| Net income | kr102.43B | kr100.99B | kr83.68B | kr55.52B | kr47.76B |
| Operating cash flow | kr119.10B | kr120.97B | kr108.91B | kr78.89B | kr55.00B |
| Free cash flow | kr58.96B | kr73.80B | kr83.10B | kr66.74B | kr48.66B |
Figures in DKK, as reported to the SEC. Longer history is available in the full analysis.
What's inside the full dashboard
Sixteen analysis tabs, all sourced from SEC filings, no estimates.
- Cash Flow: Free cash flow generation and operating cash flow trends.
- Intrinsic Value: Discounted cash flow (DCF) valuation and enterprise multiples.
- Liquidity & Leverage: Balance-sheet strength: assets, liabilities, debt and liquidity ratios.
- Margins: Gross, operating, and net profit margin analysis.
- Returns: Return on equity, return on assets, and return on invested capital.
- Revenue & Income: Revenue growth, composition, and year-over-year income trends.
- Working Capital: Working-capital efficiency, cash conversion and asset-turnover metrics.
- Risk: Debt levels, liquidity ratios, and financial risk indicators.
- Insider: Insider stock transactions and executive activity.
- Commitments: Operating leases, purchase commitments, and future obligations.
To see more, create a free account.
Create free accountUnlock the full Novo Nordisk A/S dashboard
Live valuation, management commentary, and peer comparison, all sourced directly from SEC filings. Free to access.